Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus cavernosum relaxation. Methods: In this 4-site, randomized controlled trial, 150 sexually active men with OAB were enrolled between June 2020 and May 2022. Participants were randomly allocated (1:2) into 2 treatment groups: (1) behavioral therapy alone (n=50) and (2) a combination of mirabegron 50 mg daily and behavioral therapy (n=100). The evaluation was based on the overactive bladder symptoms score (OABSS), the International Index of Erectile Function, the ejaculatory domain short form, the International Prostate Symptom Score, patient perception of bladder condition, quality of life, and urodynamic parameters. The therapeutic outcomes were assessed at baseline, 4 weeks, and 12 weeks. Results: There were 65 patients (65%) in the combination subgroup and 36 patients in the behavioral therapy who completed all 12 weeks of treatment. Both groups had a statistically significant improvement in OABSS after 12 weeks of treatment. The combination therapy group achieved a statistically significant improvement in all 4 subscores of OABSS, however, the urinary frequency (P=0.120) and urinary incontinence (P=0.234) subscores in the behavioral therapy only group did not show a significant change. Additionally, the combination group had a significant improvement in functional bladder capacity, which was not seen in the behavioral therapy group. However, both groups did not have a significant change in erectile or ejaculatory function. Conclusions: Behavioral therapy combined with mirabegron had more significant impact on the improvement of OAB than behavior therapy alone. However, both groups did not have significant changes in erectile or ejaculatory function.
Abstract
Purpose: We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus cavernosum relaxation. Methods: In this 4-site, randomized controlled trial, 150 sexually active men with OAB were enrolled between June 2020 and May 2022. Participants were randomly allocated (1:2) into 2 treatment groups: (1) behavioral therapy alone (n=50) and (2) a combination of mirabegron 50 mg daily and behavioral therapy (n=100). The evaluation was based on the overactive bladder symptoms score (OABSS), the International Index of Erectile Function, the ejaculatory domain short form, the International Prostate Symptom Score, patient perception of bladder condition, quality of life, and urodynamic parameters. The therapeutic outcomes were assessed at baseline, 4 weeks, and 12 weeks. Results: There were 65 patients (65%) in the combination subgroup and 36 patients in the behavioral therapy who completed all 12 weeks of treatment. Both groups had a statistically significant improvement in OABSS after 12 weeks of treatment. The combination therapy group achieved a statistically significant improvement in all 4 subscores of OABSS, however, the urinary frequency (P=0.120) and urinary incontinence (P=0.234) subscores in the behavioral therapy only group did not show a significant change. Additionally, the combination group had a significant improvement in functional bladder capacity, which was not seen in the behavioral therapy group. However, both groups did not have a significant change in erectile or ejaculatory function. Conclusions: Behavioral therapy combined with mirabegron had more significant impact on the improvement of OAB than behavior therapy alone. However, both groups did not have significant changes in erectile or ejaculatory function.
참고문헌 (27)
- Chuang YC, "Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study", Low Urin Tract Symptoms, 11, pp.48~55 (2019)
- Irwin DE, "Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries:results of the EPIC study", Eur Urol, 50, pp.1306~1314 (2006)
- Stewart WF, "Prevalence and burden of overactive bladder in the United States", World J Urol, 20, pp.327~336 (2003)
- Irwin DE, "Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men", J Sex Med, 5, pp.2904~2910 (2008)
- Coyne KS, "The impact of OAB on sexual health in men and women : results from EpiLUTS", J Sex Med, 8, pp.1603~1615 (2011)
- Gur S, "Mirabegron causes relaxation of human and rat corpus cavernosum : could it be a potential therapy for erectile dysfunction?", BJU Int, 118, pp.464~474 (2016)
- Yilmaz-Oral D, "Mirabegron, a selective β3-adrenoceptor agonist causes an improvement in erectile dysfunction in diabetic rats", Exp Clin Endocrinol Diabetes, 129, pp.296~302 (2019)
- Karakus S, "Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction : a 12-week pilot study", Int J Impot Res, 34, pp.588~592 (2022)
- Elbaz R, "Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction : a randomized controlled trial", Int J Urol, 29, pp.390~396 (2022)
- 강태욱, "Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review", International Neurourology Journal, 25(3), pp.182~191 (2021), 대한배뇨장애요실금학회[DOI]
- Burgio KL, "Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men : a randomized clinical trial", JAMA Intern Med, 180, pp.411~419 (2020)
- Wu TH, "Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms", J Chin Med Assoc, 83, pp.55~59 (2020)
- Lightner DJ, "Diagnosis and treatment of overactive bladder(non-neurogenic)in adults : AUA", SUFU Guideline Amendment 2019, 2019, pp.202, 558~563
- Nambiar AK, "European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence", Eur Urol, 82, pp.49~59 (2022)
- Gacci M, "European Association of Urology guidelines on male urinary incontinence", Eur Urol, 82, pp.387~398 (2022)
- Goode PS, "Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence : a randomized controlled trial", JAMA, 305, pp.151~159 (2011)
- Burgio KL, "Behavioral versus drug treatment for overactive bladder in men : the Male Overactive Bladder Treatment in Veterans(MOTIVE)Trial", J Am Geriatr Soc, 59, pp.2209~2216 (2011)
- Mattiasson A, "Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen : results from a randomized study", BJU Int, 105, pp.1126~1135 (2010)
- Klutke CG, "Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication", J Urol, 181, pp.2599~2607 (2009)
- Burgio KL, "Combined behavioral and drug therapy for urge incontinence in older women", J Am Geriatr Soc, 48, pp.370~374 (2000)
- Mattiasson A, "Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder", BJU Int, 91, pp.54~60 (2003)
- Burgio KL, "Behavioral therapy to enable women with urge incontinence to discontinue drug treatment : a randomized trial", Ann Intern Med, 149, pp.161~169 (2008)
- Lin CT, "Perspectives of medical treatment for overactive bladder", Urol Sci, 31, pp.91~98 (2020)
- Sebastianelli A, "Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms", overactive bladder : comparison with placebo and tolterodine, 2018, pp.25, 196~205
- Kuo HC, "Results of a randomized, double-blind, parallel-group, placebo- and activecontrolled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia", Neurourol Urodyn, 34, pp.685~692 (2015)
- Diederichs W, "The sympathetic role as an antagonist of erection", Urol Res, 19, pp.123~126 (1991)
- Cirino G, "Involvement of β3-adrenergic receptor activation via cyclic GMP-but not NO-dependent mechanisms in human corpus cavernosum function", Proc Natl Acad Sci U S A, 100, pp.5531~5536 (2003)